Can I read Valaciclovir as a Single Dose During Prodrome of Herpes Facialis: a Pilot Randomized Double-blind Clinical Trial on EtoBox?

Valaciclovir as a Single Dose During Prodrome of Herpes Facialis: a Pilot Randomized Double-blind Clinical Trial by O. Chosidow; Y. Drouault; R. Garraffo; P. Veyssier; For the Valaciclovir Herpes Facialis Study Group is a Medicine article available to read on EtoBox.

What is Valaciclovir as a Single Dose During Prodrome of Herpes Facialis: a Pilot Randomized Double-blind Clinical Trial about?

## Background: Randomized clinical trials of valaciclovir in recurrent herpes labialis are lacking. ## Objectives: To determine whether a single course of valaciclovir, i.e. 500, 1000 or 2000 mg, administered during the prodrome of herpes facialis, could be beneficial. ## Methods: Three hundred and forty-five out-patients with herpes labialis were screened and randomized for a multicentre, double-blind clinical trial. ninety-six patients had no recurrence after 6 months of follow-up; 249 patients were finally included in the intent-to-treat (itt) population. the main outcome measure was the rate of aborted episodes at day 3. the three treatment groups were similar at baseline. ## Results: There was no statistically significant difference between the groups in rates of aborted lesions at day 3 in the itt population, in particular between the 500 mg and 2000 mg treatment groups. ## Conclusions: Although a placebo group was not included in this pilot study, a single dose of valaciclovir was not considered beneficial in patients with recurrent herpes facialis.

Who reads Valaciclovir as a Single Dose During Prodrome of Herpes Facialis: a Pilot Randomized Double-blind Clinical Trial?

Author

O. Chosidow; Y. Drouault; R. Garraffo; P. Veyssier; For the Valaciclovir Herpes Facialis Study Group

Publisher

Oxford University Press (OUP)

Published

2003

Language

EN

Field

Medicine (Health Sciences)